Etoposide combination therapy for small cell carcinoma of the lung

Sixty-three consecutive patients with small cell carcinoma of the lung were treated by six cycles at 3-week intervals of etoposide 120 mg/m2 i.v. on day 1 and orally on days 2-5, adriamycin 40 mg/m2 i.v. on day 1 and vincristine 1.4 mg/m2 i.v. on day 1. Tumour bed irradiation was administered to pat...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 1987-01, Vol.20 (1), p.83-84
Main Authors: ABRATT, R. P, WILLCOX, P. A, HEWITSON, R. H
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic agents
Biological and medical sciences
Carcinoma, Small Cell - drug therapy
Carcinoma, Small Cell - radiotherapy
Chemotherapy
Doxorubicin - therapeutic use
Drug Administration Schedule
Etoposide - therapeutic use
Female
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - radiotherapy
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Vincristine - therapeutic use
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sixty-three consecutive patients with small cell carcinoma of the lung were treated by six cycles at 3-week intervals of etoposide 120 mg/m2 i.v. on day 1 and orally on days 2-5, adriamycin 40 mg/m2 i.v. on day 1 and vincristine 1.4 mg/m2 i.v. on day 1. Tumour bed irradiation was administered to patients with limited disease after chemotherapy. In limited-disease and extensive-disease patients the median survival was 12 and 6 months respectively. The 2-year survival rate (life table) in limited-disease patients was 26%. Treatment morbidity was low. A prospective randomised trial is being undertaken to further evaluate the role of oral etoposide in combination chemotherapy.
ISSN:0344-5704
1432-0843
DOI:10.1007/BF00252967